Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in Jiangxi Province, with a total of 19,641 enterprises reported as of January-November 2025, marking an increase of 542 enterprises or a year-on-year growth of 2.84% [1] - The proportion of Jiangxi's industrial enterprises accounts for 3.74% of the national total [1] - The report referenced is the "2026-2032 China Industrial Cloud Industry Market Deep Assessment and Investment Opportunity Forecast Report" published by Zhiyan Consulting [1] Group 2 - The data on the number of industrial enterprises in Jiangxi Province from 2016 to January-November 2025 is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting [2] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services for investment decisions [2]

2025 年度持续督导定期现场检查报告 | 保荐机构名称：招商证券股份有限公司 | 被保荐公司简称：同和药业 | | | | | --- | --- | --- | --- | --- | | 保荐代表人姓名：鄢坚 | 联系电话：0755-8294 3666 | | | | | 保荐代表人姓名：贾音 | 联系电话：0755-8294 3666 | | | | | 现场检查人员姓名：鄢坚 | | | | | | 现场检查对应期间：2025年度 | | | | | | 现场检查时间：2025年12月22日至2025年12月23日 | | | | | | 一、现场检查事项 现场检查意见 | | | | | | （一）公司治理 | | 是 | 否 | 不适用 | | 现场检查手段（查阅公司章程和各项规章制度；查阅了三会议事规则、三会会议资料、信息披露 | | | | | | 文件，并与公司相关人员进行了访谈等。） | | | | | | 1.公司章程和公司治理制度是否完备、合规 | | √ | | | | 2.公司章程和股东会、董事会规则是否得到有效执行 | | √ | | | | 3.股东会、董事会会议记录是否完整 ...

招商证券股份有限公司 关于江西同和药业股份有限公司 2025 年持续督导培训情况的报告 深圳证券交易所： 招商证券股份有限公司（以下简称"招商证券"、"保荐机构"）根据《证券 发行上市保荐业务管理办法》、《深圳证券交易所上市公司保荐工作指引》等法规 的要求对江西同和药业股份有限公司（以下简称"同和药业"、"公司"），于 2025 年 12 月 26 日开展了 2025 年持续督导培训，现将相关情况报告如下： 一、本次持续督导培训的基本情况 （一）培训时间：2025 年 12 月 26 日 （五）培训内容： 保荐机构通过现场授课的方式对公司董事、高级管理人员及其他相关人员进 行了培训，本次培训介绍了上市公司募集资金相关监管规定及要求，同时针对新 修订的《上市公司治理准则》进行了讲解。 现场培训期间，接受培训人员认真配合保荐机构的培训工作，并积极进行交 流沟通，保证了本次培训的顺利开展。通过本次培训，公司的董事、高级管理人 员及大股东对募集资金使用监管规则、上市公司治理准则有了更为明确的认识。 本次持续督导培训总体上提高了公司及其董事、高级管理人员和相关人员的规范 运作意识及对资本市场的理解，取得了良好的效果。 ...

Core Insights - The refinancing scale in the Shanghai Stock Exchange (SSE) has reached nearly 690 billion yuan in 2025, significantly supporting the optimization of capital structures and enhancing technological innovation and industrial upgrades for listed companies [1] Group 1: Refinancing Efficiency - The efficiency of refinancing review in the SSE has improved significantly in 2025, with a notable acceleration following the implementation of the "1+6" policy measures for the Sci-Tech Innovation Board on June 18 [2] - As of December 19, 2025, the review cycle for refinancing projects has been compressed to around 2 months, with some projects approved in as little as 40 days [3] Group 2: Simplified Procedures - The simplified procedure for refinancing has proven effective, allowing companies to quickly raise funds without extensive review processes, thus enhancing financing efficiency [4] - Companies like Zhimingda have successfully utilized the simplified procedure to raise 208 million yuan for research and development projects, addressing urgent financing needs [4] Group 3: Support for High-Tech Enterprises - The "light asset, high R&D investment" standard has been adopted by 14 companies on the Sci-Tech Innovation Board, allowing them to raise a total of 35.12 billion yuan, thus facilitating innovation and growth [6][7] - This standard has become a primary choice for high-growth "hard tech" companies, with significant participation from sectors such as new-generation information technology and biomedicine [7][8]

Core Viewpoint - The article discusses the trend of public funds hiring managers with pharmaceutical backgrounds to enhance their portfolios, particularly in the context of a market correction in the innovative drug sector as the year-end approaches [1][2]. Group 1: Hiring Trends - Several non-pharmaceutical themed funds have recently announced the hiring of managers with pharmaceutical expertise, indicating a shift towards a more balanced investment strategy [2][3]. - The hiring of these managers is seen as a response to the need for diversified portfolio management amid increasing market volatility and sector rotation [5][6]. Group 2: Fund Examples - Silver华 Fund announced the hiring of Wu Ying, a manager with a strong pharmaceutical background, for its Silver华乐享生活 mixed fund, which previously focused heavily on semiconductor stocks [3][4]. - Similarly, Ping An Fund appointed Fang Junping, another pharmaceutical investment veteran, to co-manage its Ping An Balanced Selection mixed fund, which had a predominant focus on real estate stocks [4][5]. Group 3: Market Outlook - The hiring of pharmaceutical managers is driven by expectations of a sustained uptrend in the pharmaceutical sector, with a focus on the upcoming performance of Chinese pharmaceutical companies [7][8]. - Analysts predict that 2026 will be a pivotal year for innovative drugs, with potential for both earnings and valuation expansion, as many companies are expected to release significant clinical data [7][8].

www.hczq.com 证券研究报告 | 医药生物 | 2025年12月13日 华创医药投资观点&研究专题周周谈 · 第154期 2025Q3实体药店市场分析 本周专题联系人：高初蕾 华创医药团队： | 首席分析师 | 郑辰 | | 执业编号：S0360520110002 | 邮箱：zhengchen@hcyjs.com | | --- | --- | --- | --- | --- | | 联席首席分析师 | | 刘浩 | 执业编号：S0360520120002 | 邮箱：liuhao@hcyjs.com | | 医疗器械组组长 | | 李婵娟 | 执业编号：S0360520110004 | 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 | | 高初蕾 | 执业编号：S0360524070002 | 邮箱：gaochulei@hcyjs.com | | 分析师 | 王宏雨 | | 执业编号：S0360523080006 | 邮箱：wanghongyu@hcyjs.com | | 分析师 | 朱珂琛 | | 执业编号：S0360524070007 | 邮箱：zhukechen@h ...

2016-2025年1-10月江西省工业企业数统计图 数据来源：国家统计局，智研咨询整理 上市公司：江西铜业（600362），安源煤业（600397），九丰能源（605090），中国稀土（000831）， 仁和药业（000650），富祥药业（300497），同和药业（300636），江中药业（600750），煌上煌 （002695），甘源食品（002991），阳光乳业（001318），百胜智能（301083），南矿集团 （001360），江铃汽车（000550） 相关报告：智研咨询发布的《2025-2031年中国工业云行业市场深度评估及投资机会预测报告》 2025年1-10月，江西省工业企业数（以下数据涉及的工业企业，均为规模以上工业企业，从2011年起， 规模以上工业企业起点标准由原来的年主营业务收入500万元提高到年主营业务收入2000万元）为19489 个，和上年同期相比，增加了562个，同比增长2.97%，占全国的比重为3.72%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、 ...

Group 1 - The company, Tonghe Pharmaceutical, stated that it ensures all investors receive equal access to information by only disclosing the number of shareholders as of the end of the reporting period in its periodic reports [2]

Core Viewpoint - Tonghua Pharmaceutical has recently received an invention patent certificate from the National Intellectual Property Administration for a compound and its preparation method, which is related to the production of the intermediate for Ticagrelor, a novel antithrombotic drug [1] Group 1: Patent Announcement - The patent pertains to a class of compounds known as dioxolane compounds and their preparation methods [1] - The invention is specifically aimed at the preparation method for the intermediate of Ticagrelor [1] Group 2: Product Information - Ticagrelor is a new type of selective small-molecule anticoagulant that can block platelet activation [1] - It is used for treating patients with acute coronary syndrome, reducing the occurrence of thrombotic cardiovascular diseases, and is characterized by its rapid and potent effects [1]

证券代码：300636 证券简称：同和药业 公告编号：2025-060 发明名称：一种二氧杂环戊烷类化合物及其制备方法和应用、替 格瑞洛中间体的制备方法 江西同和药业股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到国 家知识产权局颁发的发明专利证书，具体情况如下： 江西同和药业股份有限公司董事会 二〇二五年十二月一日 1/ 1 专利号：ZL 2024 1 1376981.X 专利类型：发明专利 专利申请日：2024.09.30 授权公告日：2025.11.28 专利权人：江西同和药业股份有限公司 本发明涉及公司产品替格瑞洛。替格瑞洛是一种新型、具有选择 性的小分子抗凝血药，可以阻断血小板活化，用于治疗急性冠脉综合 征患者，减少血栓性心血管疾病的发生，具有快速、强效的特点。 本发明提供一种二氧杂环戊烷类化合物及其制备方法，并将该化 合物用于制备替格瑞洛中间体。本发明提供的化合物和制备方法生产 成本低、产物收率高、三废少、安全性高，适合于工业化大生产。 上述发明专利的取 ...